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INTRODUCTION
Hormone therapy for prostate cancer is not gen-
erally considered to achieve the complete cure
seen with surgical treatment or radiotherapy, with
tumor-depression effects supposedly disappearing
following discontinuation of hormone therapy.
Hormone therapy for prostate cancer is thus posi-
tioned as a standard treatment for metastatic prostate
cancer at present, but as shown in the CaPSURE
database, the proportion of hormone therapy for lo-
calized prostate cancer has tended to increase rap-
idly in recent years (1). Particularly in Japan, hor-
mone therapy has been used rather than surgical
treatment for early-stage localized prostate cancer
in many cases, unlike the situation in Europe and
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America. This difference is probably closely related
to the health insurance system in Japan.
A recent study reported that discontinuation of
medical treatment after long-term hormone therapy
for localized prostate cancer causes no relapse of
cancer (2). That report has attracted a great deal of
attention. If prostate cancer can be controlled by
long-term hormone therapy, subsequently enabling
discontinuation of medical treatment, this finding
will have great significance.
Accordingly, to confirm the effects of long-term
hormone therapy for prostate cancer, a multi-center
investigation was undertaken to determine whether
discontinuation of medical treatment results in re-
lapse among clinically controlled cases that have re-
ceived long-term hormone therapy for non-metas-
tatic prostate cancer.
PATIENTS AND METHODS
Between 2005 and 2010, hormone therapy was
discontinued in our institutions for 31 patients with
non-metastatic prostate cancer (clinical stage B-C)
after receiving5 years of hormone therapy with
PSA levels maintained less than 0.5 ng/ml. In con-
tents of hormone therapy, luteinizing hormone-re-
leasing hormone (LH-RH) agonist monotherapy
and maximal androgen blockade (MAB) therapy
were included. LH-RH agonist (Goserelin acetate
10.8 mg or leuprorelin acetate 11.25 mg) was ad-
ministered subcutaneously every three months. In
the case of MAB therapy, flutamide (375 mg/day)
or bocalutamide (80 mg/day) was administered
orally in addition to LH-RH agonist. However, pa-
tients who had also received surgery or radiother-
apy were excluded. All participants in this study
agreed to discontinue treatment and the study pro-
tocols were approved by the ethics review board at
our hospital. PSA and testosterone levels were meas-
ured within 1 month before the discontinuation of
hormone therapy. After confirming the absence of
metastatic lesions on bone scintigraphy and com-
puted tomography of the chest, abdomen and pelvis,
hormone therapy was discontinued. PSA and testos-
terone levels were then measured every 1-3 months
after discontinuation of therapy. Imaging examina-
tions were performed as needed. For the purposes
of this study, PSA relapse was defined as PSA level
4.0 ng/ml. When PSA relapse or a recurrent le-
sion was confirmed, hormone therapy was resumed.
However, when patients wished the resumption of
hormone therapy, their wishes were approved in
any cases. And we treated these cases as censored
data. Testosterone level1.0 ng/ml was defined as
the castration level, so a level1.0 ng/ml indicated
significant recovery from castration level in this
study.
The primary end-point was the non-relapse pe-
riod for PSA level after discontinuation of hormone
therapy. The secondary end-point was the duration
required to recover from castration level of testos-
terone after discontinuation of hormone therapy.
RESULTS
Mean PSA level for the 31 patients at the diag-
nosis of prostate cancer was 26.0 ng/ml (range, 2.2-
186.0), and clinical stage was B in 22 patients, and
C in 9 patients. Gleason score was6 in 16 patients,
3+4 in 5 patients, 4+3 in 3 patients, and8 in 7 pa-
tients. Mean age at discontinuation of hormone ther-
apy was 78.7 years (range, 66-90), and mean dura-
tion of hormone treatment was 64.5 months (range,
60-96). Hormone therapy comprised LH-RH agonist
alone in 4 patients, MAB in 19 patients, and altera-
tion from MAB therapy to LH-RH agonist alone in
8 patients (Table 1).
Overall mean duration of follow-up was 25.5
Table 1 Patient and tumor characteristics (n=31)
Value
Age at end of endocrine therapy (years)
Mean 78.7
Range 66-90
PSA value at diagnosis of prostate cancer (ng/ml)
Mean 26.0
Range 2.2-186.0
Duration of endocrine therapy (months)
Mean 64.5
Range 60-96
Contents of endocrine therapy (n)
LH-RH agonist alone 4
MAB therapy 19
MAB→LH-RH agonist alone 8
Clinical stage (n)
Stage B 22
Stage C 9
Gleason score (n)
6 16
3+4 5
4+3 3
8 7
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months (range, 14-57). Two of the 31 patients re-
quested resumption of hormone therapy during
this study. PSA relapse was identified in 4 patients
(12.9%), with non-relapse in 27 (87.1%). Mean dura-
tion of follow-up was 18.3 months (range, 15-20) for
PSA relapse cases, compared to 25.6 months (range,
13-57) for PSA non-relapse cases. No prostate can-
cer-specific deaths were identified during this study
(non-specific death, 4 patients).
Viewing the transition of PSA levels after discon-
tinuation of hormone therapy, the 4 patients who
developed PSA relapse showed increases in the
early stage after discontinuation, and PSA relapse
was confirmed in all 4 patients within 12-24 months
(Figure 1). In terms of testosterone level after dis-
continuation of hormone therapy, recovery to above
castration level was found in 3 patients from an early
stage, with levels maintained below castration level
during follow-up in all other cases (Figure 2). All 3
patients with testosterone recovery to above castra-
tion level developed PSA relapse.
Comparison of parameters between PSA non-re-
lapse and relapse cases showed that median PSA
level in relapse cases at the time of prostate cancer
diagnosis tended to be higher (19.5 ng/ml ; range,
11.1-186.0) than in non-relapse cases (9.8 ng/ml ;
range, 2.2-70.5). In addition, median age at discon-
tinuation of hormone therapy tended to be lower in
Figure 1 : Changes in PSA level after discontinuation of hormone therapy.
PSA level4.0 ng/ml was defined as PSA relapse in this study (outside the blue area in Figure 1). The color lines showed the change
of PSA level of each cases.
Four patients experienced PSA relapse from 12 months to 24 months after discontinuation of treatment.
Figure 2 : Changes in testosterone level after discontinuation of hormone therapy.
Testosterone level1.0 ng/ml indicated significant recovery from castration level in this study (outside the blue area in Figure 2).
The color lines showed the change of testosteron level of each cases.
Recovery to above castration level was found in 3 patients and all 3 patients developed PSA relapse.
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relapse cases (74 years ; range, 66-76) than in non-
relapse cases (80 years ; range, 67-90). Conversely,
no specific tendencies in clinical stage or Gleason
score at diagnosis were observed, and non-relapse
cases included patients with stage C or Gleason
score 4+3 or8. Also, contents of long-term hor-
mone therapy and duration of hormone therapy
showed no specific tendencies between groups. Fi-
nal testosterone level and median rate of testoster-
one increase were 0.29 ng/ml (range, 0.10-1.27)
and 0.005 ng/ml/month in non-relapse cases, and
3.35 ng/ml (range, 0.36-7.29) and 0.246 ng/ml/
month in relapse cases. Both the final level and rate
of increase were higher in relapse cases than in non-
relapse cases (Table 2).
DISCUSSION
Hormone therapy has held a place as one of the
key treatment strategies for prostate cancer since
Huggins et al. reported its efficacy in 1941 (3). Hor-
mone therapy is chosen for treatment of localized
prostate cancer more often in Japan than in Europe
and America. In a study of cancer-specific survival
rates for prostate cancer treated using hormone
therapy as the initial therapy, Akaza et al. reported
good results of 91% at 5 years and 78% at 10 years
(4). Similarly, Ueno et al. reported an 8-year sur-
vival rate of 89.1% (5). However, the likelihood of
radical cure of prostate cancer by hormone therapy,
and the subsequent clinical results at discontinu-
ation of hormone therapy, have remained unclear
until now, leaving room for argument.
Concerning the likelihood of radical cure, Labrie
et al. reported in 2002 that 90% of patients with Stage
B or C prostate cancer treated using hormone ther-
apy for6.5 years showed no relapse of PSA during
5 years of follow-up (1). As a theory supporting the
radical cure of prostate cancer by hormone ther-
apy, Namiki et al. stated that “In the progressive
cancer stage, hormone therapy-refractory prostate
cancer cells increase in 3-4 years, and as a result,
hormone therapy-resistance comes to be shown.
In contrast, hormone-naive monoclonal cells in the
early stage may be susceptible to apoptosis from
hormone therapy. Radical cure for prostate cancer
may thus be quite possible” (6).
No patients in this study had metastatic prostate
cancer, and all patients had PSA0.5 ng/ml, rep-
resenting stable disease status after continuing hor-
mone therapy for5 years. However, patients with
high PSA at diagnosis, high Gleason score, and
stage C disease, representing so-called high-risk
patients, were included. Even so, only 4 of 31 pa-
tients showed PSA relapse after discontinuation of
treatment during the mean follow-up period of 25.5
months. Furthermore, the 27 PSA non-relapse cases
included 10 of the 12 high-risk patients. Likewise,
in this study, the 3 patients in whom testosterone
level returned to above castration level after discon-
tinuation of hormone therapy experienced PSA re-
lapse in the same period. Only 1 patient (stage C ;
PSA, 184 ng/ml and GS 5+4 at diagnosis) experi-
enced PSA relapse without a recovery in testoster-
one level. Given these results, not the radical cure
of prostate cancer by long-term hormone therapy
suggested by Labrie et al. , but rather the speed of
recovery in blood testosterone level after long-term
Table 2 Comparison between each parameter in PSA non-
relapse and relapse cases
PSA non-relapse
(n=27)
PSA relapse
(n=4)
PSA value at diagnosis of prostate
cancer (ng/ml)
Median 9.8 19.5
Range 2.2-70.5 11.1-186.0
Clinical stage (n)
Stage B 19 3
Stage C 8 1
Gleason score (n)
6 14 2
3+4 5 0
4+3 3 0
8 5 2
Contents of endocrine therapy (n)
LH-RH agonist alone 4 0
MAB therapy 17 2
MAB→LH-RH agonist alone 6 2
Duration of endocrine therapy
(months)
Median 61.0 68.0
Range 60-62 60-96
Age at end of endocrine therapy
(years)
Median 80 74
Range 67-90 66-76
Final testosterone level (ng/ml)
Median 0.29 3.35
Range 0.10-1.27 0.36-7.29
Rate of testosterone increase (ng/
ml/month)
Median 0.005 0.246
Range -0.006-0.052 0.011-0.436
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hormone therapy was the factor exerting the great-
est influence on PSA relapse.
Studies of blood testosterone levels after discon-
tinuation of hormone therapy have reported substan-
tial variations in results. Wilke et al. reported that
when treatment was discontinued after hormone
therapy for24 months, testosterone level exceeded
castration level in 75% of patients within 6 months
after treatment discontinuation (7). Conversely,
Kaku et al. reported that when treatment was dis-
continued after hormone therapy for a mean of 30
months, testosterone level returned to above castra-
tion level within 2 years in 90% of patients (8). Ac-
cording to the reports of Nejat et al. and Oefelein
et al. , patients who have received long-term LH-
RH agonists require longer to achieve recovery of
testosterone levels (9, 10).
In the present study, hormone therapy was contin-
ued for longer (60 months) than in previously re-
ported cases, and very few cases (approximately 10%)
showed testosterone levels returning to above cas-
tration level during follow-up (mean, 25.5 months).
These results suggest the possibility of delaying re-
covery of testosterone levels with long-term hor-
mone therapy. However, no difference in duration
of treatment was apparent between those patients in
whom testosterone level returned to above castra-
tion level and those in whom no such recovery was
recognized. Some reports have stated that the du-
ration of hormone therapy is unrelated to the speed
of testosterone recovery after discontinuation of hor-
mone therapy (11). This issue requires clarification
in future studies.
In addition, some reports have suggested that re-
covery is delayed in proportion to the age during the
period of testosterone recovery after hormone ther-
apy (10, 12). Mean age at discontinuation of hor-
mone therapy was 73 years (range, 71-76) in patients
with testosterone recovery and 80 years (range, 67-
90) in patients without testosterone recovery, and
many patients without testosterone recovery were of
advanced age. However, the small number of cases
showing testosterone recovery meant that adequate
statistical evaluations could not be performed in this
study. When predicting factors of testosterone recov-
ery are specified by further study, appropriateness for
the adaptation of discontinued, or intermittent hor-
mone therapy for aged people may be made clear.
In conclusion, among 31 patients with non-metas-
tatic prostate cancer and PSA maintained less than
0.5 ng/ml after5 years of hormone therapy, we
discontinued hormone therapy, then confirmed and
examined the presence of PSA relapse and changes
in testosterone level. During follow-up (mean, 25.5
months), the PSA non-relapse rate was quite high
(87.1%). These results suggest that many prostate
cancer patients receiving treatment may be safely
discontinued. In addition, the present findings sug-
gest that a factor exerting major influence on PSA
relapse was the speed of testosterone recovery after
discontinuation of the treatment, not the radical cure
of prostate cancer by long-term hormone therapy.
Judgments on when to discontinue hormone therapy
may be possible in the future if factors can be iden-
tified predicting the rate of testosterone recovery
after discontinuation of long-term hormone therapy.
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